Navigation Links
Tufts receives patent for antibody treatment against hemolytic uremic syndrome
Date:2/28/2011

Grafton, Mass., February 28, 2011 Researchers at the Cummings School of Veterinary Medicine have received U.S. patent approval for an antibody-based treatment for Hemolytic Uremic Syndrome (HUS), a potentially fatal outcome of E. coli poisoning and the leading cause of kidney failure in children.

HUS is caused by the forms of E. coli that produce Shiga toxins and are responsible for about 100,000 annual cases of illness in the United States alone. Typically, individuals will develop bloody diarrhea and recoverhowever, 5-15 percent of children, the elderly and individuals whose immune systems are compromised may develop HUS in addition after several days.

The condition causes kidney damage and can lead to chronic, irreversible kidney dysfunction, which can be fatal. HUS can also cause damage to the central nervous system. There is currently no cure for the condition.

The condition is believed to be caused by one of the two types of Shiga toxin excreted by E. coli, known as Stx2 and Stx1. The Tufts approach to treating HUS, led by Dr. Saul Tzipori, director of the Cummings School's Division of Infectious Diseases, utilizes human monoclonal antibodies that seek out and bind to the Stx and, ultimately, neutralize it. In a 2004 study, Dr. Tzipori was able to show its efficacy both in vitro and in vivo using mice and pig models.

Other attempts to neutralize Stx have been attempted using other types of antibodieschimeric and humanizedwhere mouse antibodies are fused with parts of human antibodies. However, Tzipori and his colleagues utilized antibodies from transgenic mice specially bred to express human antibodiescreating a safer, longer-lasting, and more effective treatment, Tzipori says.

"In addition to the other benefits, utilizing this approach of generating human antibodies enabled us to create a large number of them from which to select," said Distinguished Professor of Microbiology and Infectious Diseases Dr. Saul Tzipori.

The patent is currently licensed to Sarasota, Fla.-based Lakewood-Amedex Inc.


'/>"/>

Contact: Tom Keppeler
508-839-7910
Tufts University, Health Sciences
Source:Eurekalert

Related medicine news :

1. Tufts Medical Center and Boston Medical Center Nurses Hold a Joint Informational Picket to Protest Unsafe Staffing and Practice Conditions
2. Impressive lineup of speakers at Tufts nutrition conference
3. Tufts researcher elected 2010 AAAS Fellow for work in superbugs and heat-stable vaccines
4. Tufts University calls for moderate approach to teaching personalized genomic testing
5. NACDD Receives Two-Year Grant From Merck & Co., Inc. to Improve Diabetes Education
6. Dr Yaghouti of Global Laser Vision Receives Patient's Choice Award for 2009
7. UT researcher receives $2.4 million to research obesity, high-risk pregnancy
8. BestMassage.com Receives Award for Customer Trust
9. Corporate Wellness Firm Limeade Receives SAS 70 Type II Report
10. Oridion Receives Frost & Sullivan's 2010 Customer Value Enhancement Award
11. Special Olympics Georgia Receives Grant from The Home Depot Foundation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... September 22, 2017 , ... PITTSBURGH...Defibrillators are ... saves lives. However, if one isn’t accessible in certain locations, the risk of ... I came up with this idea," said an inventor from Ridgecrest, Calif. , ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... Safe Is Smart Scholarship Sweepstakes.,  , Molli C., a graduate student from Sonora, ... Educational Leadership and Administration at St. Thomas University in Miami, Florida, was selected ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... emergency rooms is celebrating the one year anniversary of its Houston-Fallbrook facility. ... said Dr. Otinwa, Facility Medical Director of First Choice Emergency Room Houston-Fallbrook. “It ...
(Date:9/22/2017)... Diego, CA (PRWEB) , ... September 22, 2017 ... ... offer groceries, wearable, and more products at customers’ doorstep. According to Smart Mart, ... Smart Mart has stated to offer wearable, and customers can find clothing at ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process ... 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , ... wrong, run afoul of The Quality System Regulation (§820.250), and Devicemakers find themselves ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... Eli Lilly and Company (NYSE: LLY ) ... and lasmiditan, two investigational treatments for migraine, at the ... place Sept. 7-10 in Vancouver . ... from an open-label study evaluating the safety and effectiveness ... mg) for the prevention of migraine. Galcanezumab is a ...
(Date:9/5/2017)... Sept. 5, 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... clinical-stage pharmaceutical company focused on the development of oral ... concluded its meeting with the U.S. Food and Drug ... formulation. At the ... pathway for submission of ORMD-0801, would be a Biologics ...
(Date:8/29/2017)... 2017 ivWatch, LLC, the leading provider of continuous monitoring ... has been awarded an Innovative Technology contract from Vizient, Inc., the ... ... in the early detection of peripheral IV infiltration and extravasation events ... The Innovative Technology contract was awarded to ...
Breaking Medicine Technology: